pharma

YOU MIGHT BE INTERESTED IN

The Global Pain Market, 2008-2023
The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.
...more details
The Global Multiple Sclerosis Market 2009-2024
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies.
...more details
The Global Anti-Addiction Market, 2008-2023
The global addiction market is significantly undervalued. The world's population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward.
...more details
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market.
...more details

CONFERENCE

...see all

6th Annual Pain Management

Innovations in analgesia from genomics to human experimental models

14th - 15th October 2009, BSG Conference Centre, London, UK

Download brochure Products

Background Info
Day 1
Day 2
Partners
Past Papers

Media Partners

Background Info

Key Speakers
• Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford
• Kevin Lee, Vice President, Drug Discovery, GlaxoSmithKline
• Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, Aalborg University
• Rolf Karlsten, Medical Science Director, AstraZeneca
• Roger Pertwee, Director of Pharmacology, GW Pharmaceuticals
• Stephen Wright, Research and Development Director, GW Pharmaceuticals
• Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, Merck, Sharp & Dohme
• Anastasia Liapi, Director, Business Development, Astellas
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Steve England, Associate Research Fellow, Pfizer
• Stephen Hammond, Chief Executive Officer, Scottish Biomedical
• Stephen Peroutka, Vice President, Neurosciences, PRA International
• William K. Schmidt, Vice President, Clinical Development, CrystalGenomics
• Nathaniel Katz, President & Chief Executive Officer, Analgesic Research
• Klaus Schaffler, Research Professor, University of Waterloo and President, Human Pharmacodynamic Research
• Luda Diatchenko, Chief Scientific Officer, Algynomics
• Jim Winkler, Vice President, Discovery and Translational Biology, Array BioPharma
• Keith Bley, Senior Vice President, Nonclinical R&D, NeurogesX

Pain costs approximately €200m in Europe¹ and $1trillion in the developed world in treatments, loss of productivity and disability payments². While therapeutic breakthroughs have been rare over the past 30 years, exciting advances are heralding much-needed and more effective analgesics^2,3. Modern lifestyles and an aging population will lead the global pain market, currently worth $35bn, to increase by a forecast 65% to $55bn by 2023³.

With an estimated 100 billion tablets or 35,000 tons of aspirin consumed annually in the United States alone, pain management continues to be among the fastest growing sectors of the global pharmaceutical market. Yet pain-related conditions frequently lack effective therapy and there are few analgesic classes- all of which have safety issues. The attrition rate for new analgesics remains stubbornly high, and prospects for even the most effective animal-tested drug is 5%. The danger of addiction to opioids remains unresolved and patents are rapidly nearing their end. Chronic conditions such as spinal cord injury, neuralgias and phantom limb pain remain vast unmet needs, and the search for new analgesics continues unabated.

Industry is responding to the challenge, with over 40 new products in the pipeline and new opportunities for reformulated compounds, as well as generics and biologicals. Insights from genomics, molecular biology, neuroimaging and human experimental models are driving targeted therapies, from receptor antagonists and ion channel modulators, to monoclonal antibodies and novel NSAIDs, many of which are now in clinical trials.

By attending Visiongain’s 6th Annual Pain Management conference, you will acquire distilled, market-focussed intelligence from outstanding speakers in key areas including:
• Rational approaches to chronic pain management with opioids and new FDA risk evaluation and mitigation strategy guidelines
• Clinical results from human experimental pain models in early drug development
• Genetic architecture of human pain perception and the molecular mechanisms underlying various types of pains
• New insights from voltage-gated sodium and calcium channel targets
• Emerging strategies in exploiting cannabinoid receptors agonists and their clinical results
• Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era
• Adequate PoC for new mechanisms
• Biomarkers for pain– from model to clinic
• Neuroimaging tools for analgesic drug discovery
• Reducing the numbers of patients in human clinical trials by eliminating non-responders
• Novel treatments for peripheral neuropathies undergoing clinical trials
• Outcome studies for neuropathic pain treatments in clinical practice and their implications for drug development and study design
• Innovative methods for conducting proof-of-concept studies
• Monoclonal antibody therapies for osteoarthritis in Phase III clinical trials
• Laser technology as a novel technique in human pain research
• The future market landscape in chronic pain
• New insights into migraine pain and the molecular basis of effective therapeutics

Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, and Professors in:
• Analgesia
• Neuropharmacology
• CNS Clinical Discovery/Nervous System Research
• Neuroscience
• Neurology
• Arthritis
• Migraine
• Medicinal Chemistry
• Healthcare
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Antibody Research and Development
• Protein Technologies
• Pre-Clinical/Clinical R&D
• Disease Genetics
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Clinical Trials
• Business Development
• Licensing and External Research
• Global Marketing and Medicine

¹ Tracey, I. (2008). Prof. Irene Tracey on fMRI and pain. Downloaded from the World Wide Web on April 8th, 2009: http://wspain.blogspot.com/2008/10/prof-irene-tracey-on-fmri-and-pain.html.
² Max, M.B. and Stewart, W.F. (2008). Molecular Epidemiology of Pain: A New Discipline for Drug Discovery. Nature Reviews Drug Discovery, 7 (8), pp. 647-658.
³ Visiongain, (2008). The Global Pain Market, 2008-2023.

Day 1

Day One, Wednesday 14th October 2009

09:20 Registration and refreshments

09:50 Opening address from the chair

William K. Schmidt
Vice President, Clinical Development
CrystalGenomics

10:00 The chronic pain market: building a roadmap to commercial success
• The market dynamics in key chronic pain indications
• Positioning your product in the pain market: when R&D meets marketing
• The future market landscape in chronic pain: gazing into the crystal ball and not seeing black swans

Anastasia Liapi
Director, Business Development
Astellas

10:40 Genetic architecture of human pain perception
• Pain perception is one of the most complex measurable traits and an aggregate of many intermediate phenotypes
• Genetic variation and environmental events mediate human pain phenotypes
• Separate vulnerability pathways underlie patient heterogeneity in chronic pain

Luda Diatchenko
Chief Scientific Officer
Algynomics

11:20 Morning refreshments

11:40 Ion channel targets to discover analgesics
• Contribution/importance of different ion channels (IC) in pain
• Developing in vitro assays, stable cell lines over-expressing recombinant human IC and DRGs
• Current assay methodologies to discover novel analgesics

Stephen Hammond
Chief Executive Officer
Scottish Biomedical

12:20 Voltage-gated sodium channels as targets for novel analgesics
• Importance of Navs in pain signalling
• Nav1.7; supporting evidence from human genetic studies
• Future prospects for finding subtype-selective compounds

Steve England
Associate Research Fellow
Pfizer

13:00 Networking lunch

14:00 Analgesic effects of a potent and selective kinase inhibitor of neurotrophin receptors TrkA, TrkB and TrkC
• The Neurotrophin / Trk pathway is a clinically validated pain target
• Small molecular inhibitors of the Trk receptor kinases can be extremely potent and selective
• Such small molecule inhibitors show efficacy in pre-clinical models of pain, such as CFA thermal hyperalgesia and mechanical allodynia, fracture pain and inflammatory (CIA) pain

Jim Winkler
Vice President, Discovery and Translational Biology
Array BioPharma

14:40 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase
• Are regulatory hurdles manageable in the USA and Europe?

William K. Schmidt
Vice President, Clinical Development
CrystalGenomics

15:20 A new potent opioid with fast return to normal GI transit
• Neo1509 is an original opioid which exhibits a full return to normal GI transit during analgesia
• Long duration of action (10 to 12 hours bolus, iv and po), as potent as morphine, no addiction in place preference assays
• Currently in regulatory preclinical development

Dr Roger Lahana
Chief Executive Officer
Neorphys

15:40 Afternoon refreshments

16:00 Emerging strategies in exploiting cannabinoid receptors agonists
• A current strategy for targeting cannabinoid receptors
• Emerging strategies for targeting cannabinoid receptors
• Results from clinical trials

Roger Pertwee
Director of Pharmacology
GW Pharmaceuticals

Stephen Wright
Research and Development Director
GW Pharmaceuticals

16:40 Panel discussion: Pain management in the 21st century: where are we and what are the prospects for the future?
Topics will include: the brain’s role in pain, new targets for the future, and peripheral mechanisms in analgesia and side-effect management. Pharmacovigilance and the role of pricing and reimbursement will also be discussed. If you would like to submit a question to the panel, please email: john.shah@visiongainglobal.com.

Panellists: Kevin Lee, Vice President, Drug Discovery, GlaxoSmithKline
William K. Schmidt, Vice President, Clinical Development, CrystalGenomics
Anastasia Liapi, Director, Business Development, Astellas
Nathaniel Katz, President, Analgesic Research

17:20 Closing remarks from the chair

17:30 Networking Drinks Reception
Take your discussions further and build new relationships in a relaxed and informal setting

Day 2

Day Two, Thursday 15th October 2009

09:20 Registration and refreshments

09:50 Opening address from the Chair

Chas Bountra
Chief Scientist, Structural Genomics Consortium
University of Oxford

10:00 Is there a role for epigenetics in the treatment of chronic pain?

Chas Bountra
Chief Scientist, Structural Genomics Consortium
University of Oxford

10:40 Migraine pain: what have we learned to date?
• To review previous and current theories of the origin of migraine pain
• To assess the clinical relevance of the various hypotheses
• To suggest an unifying mechanism to explain migraine pain as well as the molecular basis of effective therapeutics

Stephen Peroutka
Vice President, Neurosciences
PRA International

11:20 Morning refreshments

11:40 Development of treatments for peripheral neuropathies
• Existing treatment options
• Preclinical research
• Growth factors
• POC modeling in humans

Theo F. Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience, Johnson & Johnson

12:20 TRPV1 agonist approaches to localized management of chronic pain
• Bases of nociceptor overactivity
• Mechanisms of TRPV1 agonist-induced desensitization
• Phase 3 clinical data for neuropathic pain

Keith Bley
Senior Vice President, Nonclinical R&D
NeurogesX

13:00 Networking lunch

14:00 Outcome of treatment in neuropathic pain in clinical practice - its implication for drug development and study design

Rolf Karlsten
Medical Science Director
AstraZeneca

14:40 Human experimental pain models in early drug development
• Translation from animal to human pain models
• Back-translation from human models to animal models
• Translating from human experimental pain models in volunteers to pain patients
• Mechanisms based proof-of-concept studies
• The concept of multi-model, multi-tissue pain models
• Integrating pain models in phase Ib studies

Lars Arendt-Nielsen
Director, Pain Research Group, Centre for Sensory-Motor Interaction
Aalborg University

15:20 Innovative methods for conducting proof-of-concept studies
• Tools to reduce sample sizes by:
- Identifying accurate pain reporters
- Measuring pain more precisely
- Measuring physical activity objectively

Nathaniel Katz
Director, Program on Opioid Risk Management, Tufts University School of Medicine and President & Chief Executive Officer
Analgesic Research

16:00 Afternoon refreshments

16:20 Laser technology as a novel technique in pain research
• Principles of laser technology in pain research
• Skin types/models to work with laser stimulation
• Validity and reproducibility of laser stimuli - ending in a database on analgesics

Klaus Schaffler
Research Professor, University of Waterloo
President, Human Pharmacodynamic Research

17:00 Panel discussion: Alternative approaches to proof-of-concept studies
Panellists will discuss issues raised in the four preceding talks concerning the development of human experimental trials for novel analgesics. If you would like to submit a question to any of the participants, please email: john.shah@visiongainglobal.com

Panelists: Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford, Formerly Vice President & Head, Biology, GlaxoSmithKline
Robert Pinnock, Director, Scientific Liaison, United Kingdom & Ireland, Merck, Sharp & Dohme
Lars Arendt-Nielsen, Director, Pain Research Group, Centre for Sensory-Motor Interaction, Aalborg University
Nathaniel Katz, President, Analgesic Research
Klaus Schaffler, Research Professor, University of Waterloo and President, Human Pharmacodynamic Research

17:30 Chair’s closing remarks

17:40 End of conference

Partners

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Future Pharmaceuticals
Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide. For further information, please visit www.futurepharmaus.com

InPharm
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com

Pharma Connections Worldwide
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. For further information please visit www.pharmaconnections.com

Channels
Channels is the first international peer-reviewed journal to focus exclusively on all aspects of ion channel and ion transporter/exchanger function. Channels publishes articles focused on all aspects of ion channel and ion transporter/exchanger function. This includes papers centered around the biophysics, structure, molecular biology, structure-function analysis, and regulation of channels and ion transport proteins, as well as their roles in health and disease. We also encourage submission of manuscripts concerned with physiological aspects that branch into areas such as neuroscience and cardiovascular sciences, provided that channels and/or transporters are the main focus of such studies. For further information, please visit www.landesbioscience.com/journals/channels

Enquiries

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's 6th Annual Pain Management 2009 conference, please contact:
Ronald Reyes Magali, +44 (0)20 7549 9934
ronald.magali@visiongainglobal.com

Past Papers

Speaker presentations are free to delegates. If you are unable to attend the event, the presentations are published two weeks after the event and are available to purchase.

Buy Now